AMV-002 is under clinical development by Anteris Technologies and currently in Phase I for Head And Neck Cancer. According to GlobalData, Phase I drugs for Head And Neck Cancer have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AMV-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AMV-002 overview
AMV-002 is under development for the treatment of head and neck cancers such as oropharyngeal squamous cell carcinoma (OPSCC), and other HPV-associated cancers. It is administered through intradermal route. The drug candidate is developed based on the optimization technology platform. The technology involves the use of codon modification and ubiquitination. Combination of the two technologies allows the production of DNA vaccines which elicit both a strong antibody response and a robust cellular response. It was also under development for the treatment of HPV infection and cervical cancer.
Anteris Technologies overview
Anteris Technologies, (Anteris Technologies), formerly Admedus Ltd develops, manufactures and distributes medical devices and technologies with focus on tissue engineering and immunotherapies. The company’s product portfolio includes ADAPT technology, a next generation bio scaffold that reengineers xenograft tissue into a pure collagen scaffold and DurAVR heart valve, a 3D single piece aortic valve that creates a wider valve opening and better blood flow. Anteris Technologies is headquartered in Brisbane, Queensland, Australia.
For a complete picture of AMV-002’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Smarter leaders trust GlobalData
Premium Insights Likelihood of Approval and Phase Transition Success Rate Model - AMV-002 in Head And Neck Cancer
Premium Insights
The gold standard of business intelligence.
